Arimidex is the trade name of Anastrazole and is an antineoplastic drug, which is primarily used in the treatment of breast cancer post surgical intervention and also to treat metastases in women post menopause. Arimidex is therefore mainly used in the chemotherapeutic treatment of breast cancer in women post menopause. Arimidex works by inhibiting the process of estrogen production which is required for the growth of carcinogenic cells. The active and inactive ingredients in Arimidex are as described below: Active Ingredients: Anastrozole is the active ingredient of Arimidex and is freely soluble in methanol, acetone, ethanol, and tetrahydrofuran, and very soluble in acetonitrile. Inactive Ingredients: Inactive ingredients of Arimidex contain lactose, magnesium stearate, hydroxypropylmethylcellulose, polyethylene glycol, povidone, sodium starch glycolate, and titanium dioxide.

Anastrozole (INN, trade name: Arimidex) is a drug indicated in the treatment of breast cancer in post-menopaUSAl women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It has the effect of decreasing the amount of estrogen that the body makes.

Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogen.

The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial represents a long-term follow-up study of 9366 women with localized breast cancer who received either anastrozole, tamoxifen, or both. After more than 5 years the group that received anastrozole had significantly better clinical results than the tamoxifen group. The trial suggested that anastrozole is the preferred medical therapy for postmenopaUSAl women with localized breast cancer that is estrogen receptor positive.